Psyence Biomedical Ltd. Files 6-K Report
Ticker: PBMWW · Form: 6-K · Filed: Dec 18, 2024 · CIK: 1985062
Sentiment: neutral
Topics: sec-filing, 6-k, press-release
TL;DR
Psyence Biomedical filed a 6-K, check the press release for deets.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on December 18, 2024, reporting information for the month of December 2024. The filing includes a press release as Exhibit 99.1. Dr. Neil Maresky, CEO and Director, signed the report on behalf of the company.
Why It Matters
This filing provides an update from Psyence Biomedical Ltd. to the SEC, which may contain important information for investors regarding the company's operations or recent developments.
Risk Assessment
Risk Level: low — This filing is a routine report and does not appear to contain significant new financial or operational information that would immediately alter risk.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- Dr. Neil Maresky (person) — Chief Executive Officer and Director
- December 18, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to report information that the company makes public in its home country.
What exhibits are included in this 6-K filing?
This filing includes Exhibit 99.1, which is a Press Release.
Who signed this Form 6-K on behalf of Psyence Biomedical Ltd.?
Dr. Neil Maresky, Chief Executive Officer and Director, signed the report.
What is the principal executive office address for Psyence Biomedical Ltd.?
The principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-18 16:27:33
Filing Documents
- tm2431260d1_6k.htm (6-K) — 10KB
- tm2431260d1_ex99-1.htm (EX-99.1) — 14KB
- tm2431260d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-129774.txt ( ) — 30KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX EXHIBIT INDEX Exhibit Description 99.1 Press Release SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 18, 2024 Psyence Biomedical Ltd. By: /s/ Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director